Sarepta Therapeutics Inc (NASDAQ:SRPT) – Equities researchers at Leerink Swann boosted their FY2019 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued to clients and investors on Monday, March 12th, according to Zacks Investment Research. Leerink Swann analyst J. Schwartz now forecasts that the biotechnology company will post earnings per share of $0.40 for the year, up from their previous forecast of $0.20. Leerink Swann currently has a “Positive” rating and a $92.00 target price on the stock. Leerink Swann also issued estimates for Sarepta Therapeutics’ FY2020 earnings at $2.75 EPS.
Other analysts have also recently issued research reports about the stock. BidaskClub upgraded shares of Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 15th. Zacks Investment Research cut shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 5th. Royal Bank of Canada restated a “buy” rating and issued a $91.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday, March 14th. UBS restated an “outperform” rating and issued a $56.51 price objective (down previously from $76.00) on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. Finally, HC Wainwright set a $75.00 price objective on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Monday, February 12th. Four research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $78.87.
Shares of Sarepta Therapeutics stock traded down $1.12 on Thursday, hitting $71.74. 759,523 shares of the company’s stock traded hands, compared to its average volume of 1,241,583. The stock has a market capitalization of $4,661.52, a price-to-earnings ratio of -43.74 and a beta of 1.29. Sarepta Therapeutics has a one year low of $28.14 and a one year high of $84.37. The company has a debt-to-equity ratio of 0.54, a quick ratio of 12.96 and a current ratio of 13.91.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.05). The business had revenue of $57.30 million for the quarter, compared to the consensus estimate of $57.33 million. Sarepta Therapeutics had a negative net margin of 32.79% and a negative return on equity of 30.59%. The business’s revenue was up 961.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.71) EPS.
A number of hedge funds have recently added to or reduced their stakes in the business. Benchmark Capital Advisors increased its holdings in Sarepta Therapeutics by 4.2% during the 4th quarter. Benchmark Capital Advisors now owns 21,250 shares of the biotechnology company’s stock worth $1,182,000 after purchasing an additional 850 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Sarepta Therapeutics by 39.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 977 shares in the last quarter. US Bancorp DE increased its holdings in Sarepta Therapeutics by 35.0% during the 4th quarter. US Bancorp DE now owns 4,224 shares of the biotechnology company’s stock worth $235,000 after purchasing an additional 1,095 shares in the last quarter. Bank of Montreal Can increased its holdings in Sarepta Therapeutics by 1.3% during the 4th quarter. Bank of Montreal Can now owns 85,707 shares of the biotechnology company’s stock worth $4,770,000 after purchasing an additional 1,103 shares in the last quarter. Finally, Shepherd Financial Partners LLC increased its holdings in Sarepta Therapeutics by 16.1% during the 4th quarter. Shepherd Financial Partners LLC now owns 9,673 shares of the biotechnology company’s stock worth $539,000 after purchasing an additional 1,340 shares in the last quarter. Hedge funds and other institutional investors own 84.98% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “FY2019 EPS Estimates for Sarepta Therapeutics Inc Lifted by Leerink Swann (SRPT)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/09/fy2019-eps-estimates-for-sarepta-therapeutics-inc-srpt-lifted-by-leerink-swann.html.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.